Ever Supreme Bio Technology - Pioneer of Cell Therapy
Ever Supreme Bio Technology has researched and developed immune and stem cell therapies, offered treatment opportunities to relevant concerns, and provided personalized precision medicine for different patient needs. We are a new drug development company devoted to multiple cell therapies.
For the research and development of new drugs, the first-phase clinical trials of new drugs for the treatment of acute myocardial infarction with umbilical cord mesenchymal stem cells (UMSC01) were approved by the FDA and TFDA in February and September 2018, respectively. In March and April of 2020, we also submitted applications to TFDA and FDA for Phase I clinical trial. Also, the treatment of malignant brain tumors with dendritic cell vaccine (ADCV01) has been approved by TFDA for clinical trials.
In response to the new coronavirus pandemic, Ever Supreme Bio Technology applied allogeneic umbilical cord mesenchymal stem cells (UMSC01) for the treatment of gracious therapy, and simultaneously applied for FDA emergency use authorization, TFDA clinical trials (CDE can help), and participated in the national team with great endeavor.
In terms of Guideline for Regarding Governing Cell Therapy Technology, Ever Supreme Bio Technology is the first biotechnology company in the country to provide dendritic cell preparations for the treating all stages of cancer by the TFDA. We also work with more than ten major hospitals nationwide, including DC-CIK, which was also approved in May 2020 for the treatment of Stage IV solid cancer, so that terminally-ill patients can be treated effectively without travelling in distance.
Ever Supreme Bio Technology expects to become a highly advanced cell drug company in the Asia-Pacific region, significantly contribute to regenerative medicine.
|2016||Ever Supreme Bio Technology Co., Ltd.was established.|
|2017||Winnning 14th Annuversary National Innovation Award for UMSC01|
|2018||Pass TFDA Inspection for UMSC01 treating acute myocardial infraction|
|2019||Honoring with MoEA subsidy on A+ Industrial Innovation R&D Program on UMSC01 treating acute myocardial infraction|
|2019||Received TFDA approval on ADCV01 Phase II clinical trials on treating GBM|
|2019||TFDA approved on treating Stage IV solid cancer patients by DC technology. First in the country to grant DC cell production under Guideline for Regarding Governing Cell Therapy Technology|
|2019||TFDA approved on treating Stage I-III solid cancer patients by DC technology. First in the country to grant DC cell production under Guideline for Regarding Governing Cell Therapy Technology|
|2019||Winning 16th Annuversary National Innovation Award for CAR001|
|2020||Honoring with MoEA subsidy on A+ Industrial Innovation R&D Program on ADCV01|
|2020||TFDA approved on UMSC01 Phase I Clinical Trials on treating acute ischemic stroke|
|2020||TFDA approved on treating Stage IV solid cancer patients by DC-CIK technology.|